XML 32 R19.htm IDEA: XBRL DOCUMENT v2.4.0.6
Taxes On Income
12 Months Ended
Dec. 31, 2011
Notes to Financial Statements  
Taxes On Income

NOTE 11 - TAXES ON INCOME
 
 
a.
Tax laws applicable to the Company and its subsidiaries
 
Taxation in the United States
 
InspireMD Inc. is taxed under US tax laws.
 
Taxation in Israel
 
InspireMD Ltd. is taxed under the Israeli income tax ordinance.
 
On December 6, 2011, the “Tax Burden Distribution Law” Legislation Amendment (2011) was published in the Official Gazette. Under this law, the previously approved gradual decrease in the corporate tax rate was cancelled. The Corporate tax rate will increase to 25% beginning 2012.
 
Taxation in Germany
 
InspireMD GmbH is taxed according to the tax laws in Germany. Accordingly, the applicable tax rates are corporate tax rate of 15.825% and trade tax rate of 15%.
 
 
b.
Tax rate applicable to the Company

Amendment of the Law for the Encouragement of Capital Investments, 1959

The Israeli Law for Encouragement of Capital Investments, 1959 (hereafter - the “law”) was amended as part of the Economic Policy Law for the years 2011-2012, which was passed in the Knesset (the Israeli parliament) on December 29, 2010 (hereafter - the “amendment”). The amendment becomes effective as from January 1, 2011.

The amendment sets alternative benefit tracks to the ones currently in place under the provisions of the Law, as follows: investment grants track designed for enterprises located in national development zone A and two new tax benefits tracks (preferred enterprise and a special preferred enterprise), which provide for application of a unified tax rate to all preferred income of the company, as defined in the amendment.

The tax rates at company level, under the law:

Years
 
Development Zone A
   
Other Areas in Israel
 
             
"Preferred enterprise"
           
2011-2012
    10 %     15 %
2013-2014
    7 %     12.5 %
2015 and thereafter
    6 %     12 %
"Special Preferred Enterprise"
               
commencing 2011
    5 %     8 %

The benefits granted to the preferred enterprises will be unlimited in time, unlike the benefits granted to special preferred enterprises, which will be limited for a period of 10 years. The benefits shall be granted to companies that will qualify under criteria set in the amendment; for the most part, those criteria are similar to the criteria that were set in the law prior to its amendment.

Under the transitional provisions of the amendment, an Israeli company will be allowed to continue and enjoy the tax benefits available under the law prior to its amendment until the end of the period of benefits, as defined in the law. The company will be allowed to set the "year of election" no later than tax year 2012, provided that the minimum qualifying investment commenced not later than the end of 2010.  On each year during the period of benefits, the company will be able to opt for application of the amendment, thereby making available to itself the tax rates as above. Company's opting for application of the amendment is irrecoverable.

Measurement of results for tax purposes under the Income Tax (Inflationary Adjustments Law), 1985 (“Inflationary Adjustments Law”), in Israel
 
Pursuant to the Israel Income Tax Law (Adjustments for Inflation), 1985 (hereinafter - the Adjustments Law), the results for tax purposes have been measured through 2007 on a real basis, based on changes in the Israel Consumer Price Index. The Company is taxed under this law.

Under the Israel Income Tax Law (Adjustments for Inflation) (Amendment No. 20), 2008 (hereinafter - the amendment), the provisions of the Adjustments Law will no longer apply to the Company in the 2008 tax year and thereafter, and therefore, the results of the Company will be measured for tax purposes in nominal terms. The amendment includes a number of transition provisions regarding the end of application of the Adjustments Law, which applied to the company through the end of the 2007 tax year.

 
c.
Carry forward tax losses

As of December 31, 2011, InspireMD Ltd. had a net carry forward tax loss of approximately $19 million. Under Israeli tax laws, the carry forward tax losses of the InspireMD Ltd. can be utilized indefinitely. InspireMD GmbH had a net carry forward tax loss of approximately $10 thousand. Under German tax laws, the carry forward tax losses of the subsidiary can be utilized indefinitely. InspireMD, Inc. had a net carry forward tax loss of approximately $500 thousand.

 
d.
Tax assessments

The Company and its subsidiaries have not been assessed for tax purposes since incorporation.

 
e.
The components of loss before income taxes are as follows:

   
Year ended December 31
 
   
2011
   
2010
   
2009
 
   
($ in thousands)
 
Profit (loss)  before taxes on income:
                 
InspireMD, Inc.
  $ (7,029 )   $ -     $ -  
InspireMD Ltd.
    (7,636 )     (3,115 )     (2,624 )
InspireMD GmbH
    2       (258 )     (53 )
    $ (14,663 )   $ (3,373 )   $ (2,677 )

Current taxes on income

The tax expenses in the amount of $2, $47 and $47 thousand for the years ended December 31, 2011, 2010 and 2009, respectively, are in respect of non-US operations.

Following is a reconciliation of the theoretical tax expense, assuming all income is taxed at the regular tax rates applicable to the company in Israel (see c. above), and the actual tax expense:
 
   
Year ended December 31
 
   
2011
   
2010
   
2009
 
   
($ in thousands)
 
Loss before taxes on income, as reported in the statements of operations
  $ 14,663     $ 3,373     $ 2,677  
Theoretical tax benefit
    (4,985 )     (1,147 )     (910 )
Increase in tax benefit resulting from permanent differences
    594       431       92  
Increase in taxes on income resulting from the computation of deferred taxes at a rate which is different from the theoretical rate
    (116 )       62       24  
Increase (decrease) in uncertain tax positions - net
    (53 )     30       30  
Decrease in theoretical tax benefit resulting from subsidiaries different tax rate
    1,385       304       214  
Change in corporate tax rates, see c above
    (545 )     -       481  
Change in valuation allowance
    3,722       367       116  
    $ 2     $ 47     $ 47  

As of December 31, 2011, 2010 and 2009, the Company determines that it was more likely than not that the benefit of the operating losses would not be realized and consequently, management concluded that full valuation allowance should be established regarding the Company's deferred tax assets.

The changes in the valuation allowance for the years ended December 31, 2011 and 2010:

   
Year ended December 31
 
   
2011
   
2010
 
   
($ in thousands)
 
Balance at the beginning of the year
  $ 3,196     $ 2,829  
Changes during the year
    3,722       367  
Balance at the end of the year
  $ 6,918     $ 3,196  

 
f.
Accounting for Uncertain Tax position

Following is a reconciliation of the total amounts of the Company's unrecognized tax benefits during the years ended December 31, 2011 and 2010:
 
   
December 31
 
   
2011
   
2010
 
   
($ in thousands)
 
Balance at beginning of year
  $ 60     $ 30  
Increase in unrecognized tax benefits
               
as a result of tax positions taken during the year
            30  
Decrease in unrecognized tax benefits
               
as a result of tax positions taken during a prior year
    (60 )        
Balance at end of year
  $ -     $ 60  

All of the above amounts of unrecognized tax benefits would affect the effective tax rate if recognized.

A summary of open tax years by major jurisdiction is presented below:

Jurisdiction
 
Years
US
    2008-2011  
Israel
    2006-2011  
Germany
    2008-2011  

 
g.
Deferred income tax:

   
December 31
 
   
2011
   
2010
 
   
($ in thousands)
 
Short-term :
           
Allowance for doubtful accounts
  $ 37     $ 36  
Provision for vacation and recreation pay
    69       38  
      106       74  
Long-term :
               
R&D expenses
    522       531  
Share based compensation
    276          
Carry forward tax losses
    6,000       2,582  
Accrued severance pay, net
    14       9  
      6,812       3,122  
Less-valuation allowance
    (6,918 )     (3,196 )
    $ -     $ -